Rising Demand For Deep Vein Thrombosis (DVT) Treatment Drives Market Growth Is Supporting Development Across The Deep Vein Thrombosis Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Deep Vein Thrombosis Market From 2026 To 2030?

The deep vein thrombosis market has consistently expanded in recent times. This market is projected to expand from $1.09 billion in 2025 to $1.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.0%. Historically, this expansion has been driven by factors such as a rise in venous thromboembolism cases, an aging demographic adopting sedentary lifestyles, an increase in hospital-based surgeries, broader access to traditional anticoagulants, and heightened understanding of dvt complications.

The deep vein thrombosis market is projected to experience consistent expansion in the coming years. It is anticipated to reach a valuation of $1.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.7%. The anticipated growth over the forecast period can be attributed to advancements in novel anticoagulant therapies, a rising preference for oral over injectable treatments, the broadening scope of homecare and remote monitoring, an increase in preventive screening programs, and improved access through online pharmacies. Concurrently, major trends expected during this period include the growing adoption of direct oral anticoagulants, a shift towards outpatient and home-based dvt management, an increased focus on early diagnosis and risk stratification, the rising use of minimally invasive interventional procedures, and the expansion of online and specialty pharmacy channels.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10616&type=smp

What Core Drivers Are Transforming The Deep Vein Thrombosis Market?

The deep vein thrombosis market is expected to witness growth propelled by the rising number of individuals who require deep vein thrombosis (DVT) treatment. DVT treatment entails managing patients with deep vein thrombosis through the administration of drugs, including anticoagulants, among others, which prevent the formation of new blood clots and inhibit the expansion of existing ones, thereby improving the disease condition. An increase in the patient population needing DVT treatment signifies a higher prevalence of deep vein thrombosis, necessitating products for DVT diagnosis, prevention, and treatment. For instance, in February 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, approximately 900,000 people in the United States could be affected each year by deep vein thrombosis, with an estimated 60,000 to 100,000 Americans dying annually from DVT or PE (pulmonary embolism). Consequently, the increasing count of individuals requiring deep vein thrombosis (DVT) treatment is a key driver for the market.

How Is The Deep Vein Thrombosis Market Structured Across Different Market Segments?

The deep vein thrombosis market covered in this report is segmented –

1) By Drug Class: Anticoagulants, Inferior Vena Cava Filters, Other Drug Class

2) By Treatment: Surgery, Drugs, Other Treatments

3) By Mode Of Administration: Injectable, Oral, Other Modes Of Action

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-users

Subsegments:

1) By Anticoagulants: Direct Oral Anticoagulants (DOACs), Vitamin K Antagonists, Low Molecular Weight Heparins, Unfractionated Heparin

2) By Inferior Vena Cava Filters: Retrievable IVC Filters, Permanent IVC Filters, Advanced IVC Filter Systems

3) By Other Drug Class: Thrombolytics, Antiplatelet Agents, Fibrinolytics, Combination Therapy

What Trends Are Impacting The Deep Vein Thrombosis Market?

Leading companies in the deep vein thrombosis market are concentrating on forging strategic alliances to facilitate the swift diagnosis of deep vein thrombosis (DVT) and maximize their profitability within the sector. These collaborations highlight a growing interest in employing AI and machine learning to enhance medical diagnostics, particularly for the quick and accurate identification of DVT. For instance, in November 2023, ThinkSono Ltd., a UK-based ultrasound AI company focused on diagnosing deep vein thrombosis, joined forces with NYU Langone Health, a US-based academic medical center, to commence the initial clinical trial of new artificial intelligence (AI)-driven ultrasound software that enables a more rapid and portable diagnosis of deep vein thrombosis (DVT). Through this collaboration, the ThinkSono Guidance System technology leverages AI to potentially detect DVT with increased speed, precision, and affordability compared to existing methods. Investigators will utilize the ThinkSono Guidance System alongside standard ultrasound scanning in patients both with and without DVT. To assess and confirm the ThinkSono system’s accuracy, the outcomes of the two methods will be compared. Furthermore, medical students from the NYU Grossman School of Medicine will assist in conducting the trial as part of their practical research curriculum.

Which Organizations Are Operating Within The Deep Vein Thrombosis Market?

Major companies operating in the deep vein thrombosis market are Abbott Laboratories, Bristol-Myers Squibb Company, Sanofi-Aventis U.S. LLC, Daiichi Sankyo Company Limited, Novartis AG, Mylan N.V., Bayer AG, Boehringer Ingelheim GmbH, Medtronic PLC, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Stryker Corporation, Cook Medical Incorporated, Boston Scientific Corporation, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Shire Pharmaceuticals, AstraZeneca PLC, Endo International plc

Access The Complete Deep Vein Thrombosis Market Report:

https://www.thebusinessresearchcompany.com/report/deep-vein-thrombosis-global-market-report

Which Region Commands The Largest Share Of The Deep Vein Thrombosis Market?

North America was the largest region in the deep vein thrombosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global deep vein thrombosis market report during the forecast period. The regions covered in the deep vein thrombosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Deep Vein Thrombosis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=10616&type=smp

Browse Through More Reports Similar to the Global Deep Vein Thrombosis Market 2026, By The Business Research Company

Deep Vein Thrombosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/deep-vein-thrombosis-global-market-report

Venous Thromboembolism Market Report 2026

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

Thrombophilia Market Report 2026

https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795